Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNCHRONY: Aleglitazar Dose-Ranging Study in Type 2 Diabetes
NCT00388518Phase 2Completed
- Sponsor
- Roche
- Start
- Nov 2006
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of aleglitazar in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Roche. Primary endpoint: Change from Baseline in Hemoglobin A1c at 16 weeks. Started Nov 2006; status: completed.
02
Drugs
aleglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00388518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00388518.